… multiple myeloma (R/R MM), highlighting the need to validate clinical trial … outcomes, assess economic impact, and ensure equitable integration into treatment …

An expert discusses how treatment guidelines and institutional pathways are evolving to integrate CAR T-cell therapies and bispecific antibodies for relapsed/refractory multiple myeloma (R/R MM), emphasizing individualized sequencing decisions, …

… determine the MTD. Pharmacokinetics, pharmacodynamics, and preliminary … treatment of patients with relapsed and/or refractory multiple myeloma … new approach to treating prostate cancer … Therapeutics receives FDA Clearance of investigational new drug (IND …

… antibodies in multiple myeloma, Atrash suggested that investigators were evaluating this treatment in … (Revlimid), and dexamethasone—the MAIA trial (NCT02252172) regimen—in the transplant … 4 (EMN30): a phase 3 trial of teclistamab + lenalidomide versus …

… engagers in patients with multiple myeloma may effectively mitigate adverse … we are talking about one drug, [fewer] steroids––and … duration of treatment. This means you treat with bispecific … amp; novel immunotargets in multiple myeloma. Presented at the 2025 …

Panelists discuss how patients educate themselves about multiple myeloma through hospital pamphlets and magazines, online research, and positive attitude books about cancer while emphasizing the critical importance of peer support and mentorship programs …

… multiple myeloma (R/R MM), until recently. In the CARTITUDE-1 trial … pathological role in the development of several hematologic … in [MM], with drugs like lenalidomide, patients can … trials in earlier treatment lines mature, pharmacists and oncology …

… proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies … Mann School of Pharmacy and Pharmaceutical Sciences in … Over time, many develop resistance to existing agents … . FDA Approvals Expand Initial Treatment Options for Multiple Myeloma. April …

… population. Patients in this trial were heavily pretreated, … -class refractory to immunomodulatory drugs, proteasome inhibitors, and … 4/5. No treatment-related deaths occurred, reinforcing … for relapsed/refractory multiple myeloma with 5-year follow …

… regimens for the treatment of patients with multiple myeloma. Although triplet … the phase 2 GRIFFIN trial (NCT02874742) and the phase … 3 PERSEUS trial (NCT03710603), she noted. The … to all patients with multiple myeloma if eligible, and triplet …